Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy
Latest Information Update: 20 Nov 2023
At a glance
- Drugs Ianalumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 10 Nov 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Jun 2023 Planned End Date changed from 7 Mar 2025 to 6 Dec 2024.
- 08 Jun 2023 Planned primary completion date changed from 7 Mar 2025 to 6 Dec 2024.